Breast Cancer Clinical Trial

A Validation Study to Determine Concordance of Liquid Biopsy and Breast Cancer Diagnosis

Summary

This study evaluates whether a special type of blood analysis, called liquid biopsy (LBx), correlates with mammography results and/or diagnosis of breast cancer.

View Full Description

Full Description

PRIMARY OBJECTIVES:

I. Determine the sensitivity of LBx for the presence of breast cancer in patient cohorts II. Determine the specificity of LBx for the presence of breast cancer in all patient cohorts.

OUTLINE: This is an observational study.

Patients undergo blood sample collection and have their medical records reviewed on study.

View Eligibility Criteria

Eligibility Criteria

Inclusion Criteria:

* Women

Age ≥ 18 years.
Screening Mammography Cohort: Patients who were referred for screening mammography and had mammography performed within 6 months prior to blood draw or will be undergoing mammography within 6 months after blood draw. Patient must not have personal history of breast cancer, history of breast biopsy or prior abnormal mammography findings are allowed. OR
Abnormal Screening Cohort: Patient who has had mammography that revealed abnormal results (BIRADS 3, 4, 5) or abnormal MRI results requiring further testing (additional imaging modality or biopsy). Patients must not have a history of breast cancer, history of breast biopsy, or prior abnormal mammography findings are allowed. The blood draw must occur in the time between the abnormal mammography and start of definitive treatment (surgery or neoadjuvant chemotherapy). Patients who have already undergone surgery/excisional biopsy due to abnormal mammography findings are not eligible. OR
New Beast Cancer Cohort: Patients with new biopsy proven diagnosis of breast cancer (invasive breast cancer or DCIS) within 60 days of blood draw who has not started any cancer directed therapy, including surgery, radiation, hormonal therapy or chemotherapy. Any breast cancer type patients at any stage are eligible. OR
Remission Breast Cancer Cohort: Patients with personal history of localized breast cancer (stage 1, 2, 3) that has been previously treated with cancer directed therapy, such as surgery, chemotherapy, radiation and/or hormonal therapy who has been in completed remission. Patients must complete their surgery, adjuvant chemotherapy and/or radiation therapy prior to enrollment. The blood draw must occur at least 90 days after completion of the specified treatment modalities. Patients on adjuvant hormonal therapy are eligible to enroll (those who are treated with adjuvant hormonal therapy in combination with CDK4/6 inhibitor must complete CDK4/6 inhibitor therapy prior to enrollment).

Exclusion Criteria:

* Patients unable to give informed consent

Patients who have received blood transfusion with 14 days prior to study blood draw
Patients who had a heart attack, stroke, or pulmonary embolism within 3 months to study blood draw
Excisional breast biopsy in the prior 30 days. Needle biopsy of the breast is permitted

Study is for people with:

Breast Cancer

Estimated Enrollment:

490

Study ID:

NCT06336928

Recruitment Status:

Not yet recruiting

Sponsor:

University of Southern California

Check Your Eligibility

Let’s see if you might be eligible for this study.

What is your age and gender ?

Submit

There are 3 Locations for this study

See Locations Near You

Keck Medicine of USC Koreatown
Los Angeles California, 90020, United States More Info
Bomi Choi
Contact
323-865-0451
[email protected]
Anastasia Martynova, MD
Principal Investigator
Los Angeles General Medical Center
Los Angeles California, 90033, United States More Info
Kimberly Arieli, RN
Contact
323-865-0451
[email protected]
Anastasia Martynova, MD
Principal Investigator
USC / Norris Comprehensive Cancer Center
Los Angeles California, 90033, United States More Info
Kimberly Arieli, RN
Contact
323-865-0451
[email protected]
Anastasia Martynova, MD
Principal Investigator
USC Norris Oncology/Hematology-Newport Beach
Newport Beach California, 92663, United States More Info
Kristy Massopust
Contact
949-474-5733
[email protected]
Anastasia Martynova, MD
Principal Investigator

How clear is this clinincal trial information?

Study is for people with:

Breast Cancer

Estimated Enrollment:

490

Study ID:

NCT06336928

Recruitment Status:

Not yet recruiting

Sponsor:


University of Southern California

How clear is this clinincal trial information?

×

Introducing, the Journey Bar

Use this bar to access information about the steps in your cancer journey.